Oncopeptides publishes report for Q1 2021 and updated dates for the publication of the reports for Q2 and Q3 2021
A strong start for PEPAXTO in the US
News provided by
Share this article
Share this article
STOCKHOLM, May 26, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the report for the first quarter 2021. Oncopeptides now stands proudly among the few companies that have successfully navigated the long and difficult path from discovery to commercialization says CEO, Marty J Duvall.
Financial overview January-March
Operating loss amounted to SEK 347.3 M (loss: 296.9)
STOCKHOLM, May 20, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological
Oncopeptides publishes the 2020 Annual Report finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Oncopeptides submits application for conditional marketing authorization of melflufen in the EU
News provided by
Share this article
Share this article
STOCKHOLM, April 16, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the Company has submitted an application to the European Medicines Agency, EMA, for conditional marketing authorization of melflufen (melphalan flufenamide) in the EU, based on the pivotal phase 2 HORIZON study in relapsed refractory multiple myeloma. Pending a positive validation from the EMA, melflufen will be subject to a regulatory assessment according to the standard timelines.